2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3650 Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial

Yan Gao, Xuan-Ye Zhang2, Xue-Ping Li3, Xiaolei Wei4, Qichun Cai, PhD5, Li-Qin Ping6, Jicheng Hong7, Huiqiang Huang, MD, PhD8
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 Sun Yat-sen University Cancer Center, Guangzhou, China
3 Sun Yat-sen University Cancer Center, Guangzhou, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, China
5 Cancer Center, Clifford Hospital, Guangzhou, China
6 The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China
7 Sun Yat-sen University Cancer Center, Guangzhou, China
8 Sun Yat-sen University Cancer Center, Guangzhou, China

Background
Elderly patients with diffuse large B-cell lymphoma (DLBCL) face treatment challenges due to comorbidities and poor tolerance of chemotherapy. With advancing age and extranodal involvement, the proportion of the ABC/non-GCB subtype increases, and complex molecular features associated with unfavorable prognosis become more frequent. These characteristics suggest distinct biological and immune microenvironment profiles in elderly DLBCL. Frontline use of anti-PD-1 antibody may represent a timely opportunity for this population. Furthermore, the activated B-cell-like subtype exhibits programmed death ligand 1 (PD-L1) overexpression through genetic alterations, which facilitates immune evasion. These findings provide a rationale for investigating anti-PD-1 blockade combined with other agents in the frontline setting to enhance therapeutic efficacy in extranodal DLBCL. At the 2025 ASH Annual Meeting, we presented results from 110 patients; herein, we provide an updated analysis of the entire cohort.

Methods
Patients aged 60–85 years with ECOG performance status 0–2, previously untreated DLBCL, and at least one measurable or evaluable lesion were enrolled. They received two cycles of toripalimab at the recommended phase 2 dose (RP2D) plus rituximab (375 mg/m²) every 3 weeks. Patients who achieved a complete response (CR) after the first two cycles were allowed to receive two additional cycles of toripalimab plus rituximab (To-Ri). To-Ri was followed by up to six cycles of R-CHOP-21. After achieving CR or complete metabolic response (CMR) post-R-CHOP, patients received six cycles of toripalimab (RP2D) maintenance every 30 days. The primary endpoints were objective response rate (ORR) per Lugano 2016 criteria and clinical benefit rate. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. A Simon’s two-stage design was used for this phase II study. Based on previous data, we assumed an expected CR rate of 0.86 (P1) and a minimum acceptable CR rate of 0.76 (P0), with α = 0.05 and β = 0.8. The optimal two-stage design was (36/46, 95/118). A total of 140 patients were enrolled. Adverse events (AEs) were graded per CTCAE v5.0. This trial is registered at   (NCT04058470).

Results
From December 2020 to June 2026, 140 eligible patients were enrolled. Key baseline characteristics included a median age of 66 years (range, 60–83) and balanced sex distribution (51.4% male). ECOG score >1 was observed in 18.6% (n = 26), while 71.4% (n = 100) had extranodal involvement, with 22.8% (n = 32) involving >2 organs. An International Prognostic Index (IPI) score ≥3 was present in 45.6% (n = 64). Molecular subtyping distribution was: GCB 29.3% (n = 41), non-GCB 66.4% (n = 93), double-expressor DLBCL 20.7% (n = 29), and double-/triple-hit DLBCL 2.9% (n = 4). RP2D of Toripalimab was 240mg. All patients were evaluable for response to the To-Ri regimen, with a median of 2 cycles administered (range, 1–4). The ORR after To-Ri was 61.4% (86/140), with a CR rate of 36.4% (51/140). Subtype-specific ORR/CR rates were: GCB 53.6%/26.8%, non-GCB 63.4%/38.7%, double-expressor 61.2%/34.5%, and double-/triple-hit 100%/50%. By involved site, nasal/nasopharyngeal disease showed the highest ORR (81.0%, 13/16), followed by breast (75%, 3/4), gastric (66.7%, 12/18), and testicular involvement (60.0%, 3/5). Among 138 patients receiving To-Ri plus R-CHOP, ORR and CR increased to 94.9% (131/138) and 89.1% (123/138), respectively. With a median follow-up of 29 months, the 2-year PFS was 85.7% (95% CI, 78.1–90.7%) and the 2-year OS was 88.4% (95% CI, 81.4–92.8%). PFS was significantly longer in patients who achieved a CR or PR after To-Ri therapy than in those without such a response (p = 0.0012). The most common treatment-related adverse events of all-grade (incidence ≥10%) included neutropenia (88.1%), lymphopenia (79.1%), anemia (88.8%), thrombocytopenia (40.5%), nausea or vomiting (26.1%), and pulmonary-related infection (23.6%).

Conclusion
The observed CR rate in this study exceeded the prespecified efficacy threshold. Toripalimab plus rituximab as frontline induction, followed by R-CHOP, yielded a high CR rate with manageable toxicity in newly diagnosed elderly DLBCL. Clinical benefit from To-Ri therapy was associated with improved PFS. This treatment strategy warrants further investigation.

Huiqiang Huang, MD, PhD: No relevant conflicts of interest to declare.